Literature DB >> 33409397

Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).

Narendra Singh Choudhary1, Ajay Duseja2.   

Abstract

Inter-individual and inter-ethnic differences and difference in the severity and progression of liver disease among patients with non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) suggests the involvement of genetic and epigenetic factors in their pathogenesis. This article reviews the genetic and epigenetic modifiers in patients with NAFLD and ALD. Evidence regarding the genetic and epigenetic disease modifiers of NAFLD and ALD was reviewed by searching the available literature. Both genome wide association studies (GWAS) and candidate gene studies pertaining to the pathogenesis in both diseases were included. Clinical implications of the available information are also discussed. Several studies have shown association of both NAFLD and ALD with I148M PNPLA3 variant. In addition to the higher prevalence of hepatic steatosis, the I148M PNPLA3 variant is also associated with severity of liver disease and risk of hepatocellular carcinoma (HCC). TM6SF2 is the other genetic variant shown to be significantly associated with hepatic steatosis and cirrhosis in patients with NAFLD and ALD. The Membrane bound O-acyltransferase domain-containing 7 (MBOAT7) genetic variant is also associated with both NAFLD and ALD. In addition to these mutations, several variants related to the genes involved in glucose metabolism, insulin resistance, lipid metabolism, oxidative stress, inflammatory pathways, fibrosis have also been shown to be the disease modifiers in patients with NAFLD and ALD. Epigenetics involving several micro RNAs and DNA methylation could also modify the disease course in NAFLD and ALD. In conclusion the available literature suggests that genetics and epigenetics are involved in the pathogenesis of NAFLD and ALD which may affect the disease prevalence, severity and response to treatment in these patients. 2021 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Non-alcoholic steatohepatitis (NASH); cirrhosis; fatty liver; hepatic steatosis; hepatocellular carcinoma (HCC)

Year:  2021        PMID: 33409397      PMCID: PMC7724177          DOI: 10.21037/tgh.2019.09.06

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  10 in total

Review 1.  Detangling the interrelations between MAFLD, insulin resistance, and key hormones.

Authors:  Shreya C Pal; Mohammed Eslam; Nahum Mendez-Sanchez
Journal:  Hormones (Athens)       Date:  2022-08-03       Impact factor: 3.419

Review 2.  Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.

Authors:  Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

3.  Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response.

Authors:  Oana Irina Gavril; Lidia Iuliana Arhire; Otilia Gavrilescu; Mihaela Dranga; Oana Barboi; Radu Sebastian Gavril; Roxana Popescu; Cristina Cijevschi Prelipcean; Anca-Victorita Trifan; Catalina Mihai
Journal:  Medicina (Kaunas)       Date:  2021-10-24       Impact factor: 2.430

Review 4.  Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis.

Authors:  Agostino Di Ciaula; Leonilde Bonfrate; Marcin Krawczyk; Gema Frühbeck; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

Review 5.  Platelets in Non-alcoholic Fatty Liver Disease.

Authors:  Andrea Dalbeni; Marco Castelli; Mirko Zoncapè; Pietro Minuz; David Sacerdoti
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

Review 6.  Epigenetics of alcohol-related liver diseases.

Authors:  Nawras W Habash; Tejasav S Sehrawat; Vijay H Shah; Sheng Cao
Journal:  JHEP Rep       Date:  2022-03-10

Review 7.  Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.

Authors:  Mohamed Zaiou
Journal:  World J Gastroenterol       Date:  2022-09-21       Impact factor: 5.374

Review 8.  Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.

Authors:  Szu-Yi Liu; I-Ting Tsai; Yin-Chou Hsu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

9.  Genetic Variants of Alcohol Metabolizing Enzymes and Alcohol-Related Liver Cirrhosis Risk.

Authors:  Pedro Ayuso; Elena García-Martín; José A Cornejo-García; José A G Agúndez; José María Ladero
Journal:  J Pers Med       Date:  2021-05-13

Review 10.  Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives.

Authors:  Marcello Dallio; Mario Romeo; Antonietta Gerarda Gravina; Mario Masarone; Tiziana Larussa; Ludovico Abenavoli; Marcello Persico; Carmelina Loguercio; Alessandro Federico
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.